Intravaginal ring providing dual protection is first of its kind to enter a clinical trial
Women’s reproductive health may never be the same, thanks to Northwestern University biomedical engineer Patrick Kiser and his first-of-its-kind intravaginal ring that reliably delivers an antiretroviral drug and a contraceptive for months.
Kiser’s one ring delivers two drugs that do three important things: the device is designed to protect against HIV and herpes as well as unwanted pregnancy. It will be the first device with the potential to offer this protection to be tested in women.
The easy-to-use ring delivers controlled doses of tenofovir (a common antiretroviral drug) and levonorgestrel (a contraceptive) for 90 days. The rings are being manufactured now, and the device soon will undergo its first test in women.
Details of the development of the ring, a device that represents a lot of ‘firsts,’ was published March 5 by PLOS ONE, a peer-reviewed, open-access online journal.
According to the World Health Organization, 35 million people around the world live with HIV, and 222 million women would like to delay or stop childbearing but are not using any method of contraception.
“I suspect women will use the ring primarily for contraception, but they also will benefit from protection against sexually transmitted diseases,” said Kiser, an expert in intravaginal drug delivery. “And for women in the developing world in particular, unwanted pregnancy can have significant health, economic and cultural consequences. We want to motivate women to use this ring.”
The ring, 5.5 centimeters in diameter, is simple yet complex. Kiser and his colleagues worked painstakingly for five years, engineering the three materials that make up the ring and optimizing the device to reliably deliver fixed and efficacious doses of two medicines over a long period of time.
“A lot of engineering has gone into developing the ring,” said Kiser, senior author of the paper. “It represents two Ph.D. theses — one Ph.D. for the larger section containing the antiretroviral drug and another Ph.D. for the smaller section containing the contraceptive.”
Kiser is a faculty member in the department of biomedical engineering at the McCormick School of Engineering and Applied Science and in the department of obstetrics and gynecology at Northwestern University Feinberg School of Medicine.
The ring is easily inserted in the vagina and stays in place for three months. And because the tenofovir is delivered at the site of transmission, the ring — known as the tenofovir levonorgestrel IVR — utilizes a smaller dose than pills. The levonorgestrel released by the ring is the same drug as that used in certain contraceptive pills and in an intrauterine device.
“This system represents a significant advance in vaginal drug delivery technology and is the first in a new class of long-acting multipurpose prevention drug delivery systems,” say the authors in the study. They also report details of the ring’s engineering, safety, stability and drug release.
“The differences between the two drugs are huge, which presented us with a design challenge,” Kiser said. “Tenofovir is highly water soluble while levonorgestrel is highly water insoluble. And the daily dose is different: the ring delivers about 10 milligrams of tenofovir and only 10 micrograms of levonorgestrel. Our scientific hurdle was finding a way to manufacture a dual-purpose ring that got the device into the clinic.”
Tenofovir is taken orally by 3.5 million HIV-infected people worldwide, and it also has been studied as a gel. The drug inhibits HIV and HSV-2 (herpes simplex virus-2) replication in susceptible cells.
Previous studies have demonstrated that antiretroviral drugs can prevent HIV infection, but existing methods for delivering the drug fall short. Pills must be taken daily and require high doses; some women may prefer a longer-lasting method, such as the ring, versus methods used at the time of sex, such as a gel.
Kiser’s combination ring promises much more. The strength of the device stems from its unique polymer construction: its elastomer swells in the presence of fluid (such as that found in the human body), delivering up to 100 times more of the tenofovir than current intravaginal ring technology, which have release rates that decline over time.
“Products only work when they are used,” said co-author David Friend, product development director at CONRAD, which develops reproductive health technologies for low-income countries and is affiliated with Eastern Virginia Medical School.
“By having a ring that can remain in the body for up to 90 days, our hope is that this ring will offer a solution to increase adherence, and therefore provide greater protection against HIV while also preventing pregnancy,” he said.
The Latest on: Birth control
via Google News
The Latest on: Birth control
- Why comparing blood clot risks from COVID-19 vaccines and birth control pills doesn’t workon April 16, 2021 at 12:33 pm
Among the most popular comparisons has been the heightened risk of clots that women taking hormonal birth control pills face. And this, in turn, has led some people to question how much the medical ...
- The Johnson & Johnson Vaccine Has Sparked a Conversation About Birth Control and Blood Clotson April 15, 2021 at 12:48 pm
In light of recent news about the J&J vaccine, people have been pointing out the rate of blood clots among people who take birth control. But can the two really be compared?
- ‘Let’s do birth control next’: TikTokers want blood clots taken more seriously after J&J vaccine pausedon April 14, 2021 at 7:04 pm
TikTokers want blood clots linked to birth control to be taken more seriously after the J&J vaccine was paused due to six cases of clots.
- Here's Why You Can't Compare The Extremely Rare J&J Vaccine Blood Clots To Ones Linked To Birth Controlon April 14, 2021 at 1:29 pm
The causes and treatments are not the same, doctors told BuzzFeed News. Still, the Johnson & Johnson pause is no reason to panic.
- We Need to Be Outraged About Birth Control Blood Clots Too | Opinionon April 14, 2021 at 11:11 am
On Tuesday, the Centers for Disease Control and Prevention and the Food Drug Administration announced a "pause" on the distribution of the single-dose Johnson & Johnson COVID-19 vaccine. More than 6.8 ...
- Biden Moves to Overturn Trump Birth Control Ruleson April 14, 2021 at 10:00 am
The Biden administration Wednesday formally proposed the repeal of Trump-era regulations barring abortion referrals and making other changes intended to evict Planned Parenthood and other abortion ...
- Understanding birth control: No one-size-fits-all solutionon April 14, 2021 at 4:46 am
Only a few decades ago, there weren't many birth control choices available. Now, there are more options than ever, because there's no one-size-fits-all solution for preventing unwanted pregnancy.
- J&J Covid vaccine, birth control, and the inherent risk of modern medicineon April 14, 2021 at 2:30 am
Informed risk is an inherent part of advancing modern medicine, whether with the J&J Covid vaccine or birth control.
- You are more likely to get a blood clot on birth-control pills than from the J&J vaccine - but not the same type of cloton April 13, 2021 at 2:57 pm
The rate of blood clots is higher among women on birth-control pills than the rate associated with J&J's vaccine. But comparing them isn't so simple.
- Don’t Compare Blood Clots After Johnson and Johnson Vaccine to Birth Control Riskon April 13, 2021 at 1:20 pm
Blood clots seen among people vaccinated with the J&J shot are different from those that can place birth control users in danger.
via Bing News